Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study
- 1 December 1989
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 25 (12) , 1675-1681
- https://doi.org/10.1016/0277-5379(89)90334-9
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- DUP 785 (NSC 368390): Schedule-dependency of growth-inhibitory and antipyrimidine effectsBiochemical Pharmacology, 1988
- Application of a new preclinical drug screening system for cancer of the large bowelCancer Chemotherapy and Pharmacology, 1988
- Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)Investigational New Drugs, 1987
- MECHANISM OF ACTION OF THE NOVEL ANTICANCER AGENT 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYL-4-QUINOLINECARBOXYLIC ACID SODIUM-SALT (NSC 368390) - INHIBITION OF DENOVO PYRIMIDINE NUCLEOTIDE BIOSYNTHESIS1986
- ACTIVITY OF A NOVEL 4-QUINOLINECARBOXYLIC ACID, NSC-368390 [6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYL-4-QUINOLINECARBOXYLIC ACID SODIUM-SALT], AGAINST EXPERIMENTAL-TUMORS1985
- Purine and pyrimidine metabolism in peripheral blood lymphocytesInternational Journal of Biochemistry, 1983